GOLDINVEST | News
Hemostemix Investor Presentation (October 17, 2024)
Rundes Icon von GOLDINVEST - Das Investor-Magazin für Rohstoff-News und Rohstoff-Aktien
Editorial Team

For further information, please contact:

🔹 Marshall Farris, Registered Dealing Representative
🔹 Phone: +1 604-837-4774
🔹 Email: marshall@ascentafinance.com

Risk Notice Disclaimer

I. Information Function and Disclaimer
GOLDINVEST Consulting GmbH offers editors, agencies, and companies the opportunity to publish comments, analyses, and news on www.goldinvest.de. The content is solely for general information and does not replace individual, expert investment advice. It does not constitute financial analysis or sales offers, nor is there a call to action to buy or sell securities. Decisions made based on the published information are made entirely at one’s own risk. No contractual relationship is established between GOLDINVEST Consulting GmbH and the readers or users, as our information relates exclusively to the company and not to personal investment decisions.

II. Risk Disclosure
The acquisition of securities involves high risks that can lead to the total loss of invested capital. Despite careful research, GOLDINVEST Consulting GmbH and its authors assume no liability for financial losses or the content guarantee regarding the timeliness, accuracy, adequacy, and completeness of the published information. Please also note our further terms of use.

III. Conflicts of Interest
In accordance with §34b WpHG and §48f Para. 5 BörseG (Austria), we point out that GOLDINVEST Consulting GmbH and its partners, clients, or employees hold shares in the above-mentioned companies. Furthermore, there is a consulting or other service contract between these companies and GOLDINVEST Consulting GmbH, and it is possible that GOLDINVEST Consulting GmbH may buy or sell shares in these companies at any time. These circumstances may lead to conflicts of interest, as the above-mentioned companies compensate GOLDINVEST Consulting GmbH for reporting.

Hemostemix Inc. is a life sciences company focused on the development and commercialization of stem cell therapies. The company concentrates on novel treatment approaches for severe conditions such as critical limb ischemia. Through its own patented technologies and advanced clinical trials, Hemostemix aims to introduce innovative therapies that could significantly impact healthcare.
Newsletter

Don't miss any news and stay informed about the commodity market at all times!

Current Videos
Share This Video